Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial
Caleb P Skipper, Katelyn A Pastick, Nicole W Engen, Ananta S Bangdiwala, Mahsa Abassi, Sarah M Lofgren, Darlisha A Williams, Elizabeth C Okafor, Matthew F Pullen, Melanie R Nicol, Alanna A Nascene, Kathy H Hullsiek, Matthew P Cheng, Darlette Luke, Sylvain A Lother, Lauren J MacKenzie, Glen Drobot, Lauren E Kelly, Ilan S Schwartz, Ryan Zarychanski, Emily G McDonald, Todd C Lee, Radha Rajasingham, David R Boulware, Caleb P Skipper, Katelyn A Pastick, Nicole W Engen, Ananta S Bangdiwala, Mahsa Abassi, Sarah M Lofgren, Darlisha A Williams, Elizabeth C Okafor, Matthew F Pullen, Melanie R Nicol, Alanna A Nascene, Kathy H Hullsiek, Matthew P Cheng, Darlette Luke, Sylvain A Lother, Lauren J MacKenzie, Glen Drobot, Lauren E Kelly, Ilan S Schwartz, Ryan Zarychanski, Emily G McDonald, Todd C Lee, Radha Rajasingham, David R Boulware
Abstract
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.
Design: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).
Setting: Internet-based trial across the United States and Canada (40 states and 3 provinces).
Participants: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.
Intervention: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo.
Measurements: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.
Results: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 point [95% CI, -0.61 to 0.07 point]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P < 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).
Limitation: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.
Conclusion: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.
Primary funding source: Private donors.
Conflict of interest statement
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-4207.
Figures
References
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. [PMID: 32150618] doi:10.1093/cid/ciaa237
- Pastick KA, Okafor EC, Wang F, et al. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 2020;7:ofaa130. [PMID: 32363212] doi:10.1093/ofid/ofaa130
- Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738. [PMID: 32387409] doi:10.1016/j.tmaid.2020.101738
- Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382:2411-2418. [PMID: 32379955] doi:10.1056/NEJMoa2012410
- Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med. 2020. [PMID: 32445440] doi:10.1056/NEJMoa2007764
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-1578. [PMID: 32423584] doi:10.1016/S0140-6736(20)31022-9
- Lother SA, Abassi M, Agostinis A, et al. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Can J Anaesth. 2020. [PMID: 32383125] doi:10.1007/s12630-020-01684-7
- Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020. [PMID: 32422057] doi:10.7326/M20-1495
- Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2: a narrative review. Ann Intern Med. 2020;172:726-734. [PMID: 32282894] doi:10.7326/M20-1301
- Council of State and Territorial Epidemiologists. Interim-20-ID-01: standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19). Accessed at on 20 April 2020.
- Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020. [PMID: 32492293] doi:10.1056/NEJMoa2016638
- Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness. Clin Pharmacol Ther. 2020. [PMID: 32344449] doi:10.1002/cpt.1874
- Harris PA, Taylor R, Minor BL, et al; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. [PMID: 31078660] doi:10.1016/j.jbi.2019.103208
- Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 — United States, January–February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:245-246. [PMID: 32134909] doi:10.15585/mmwr.mm6909e1
- World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). February 2020. Accessed at on 9 March 2020.
- Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-50. [PMID: 10866439]
- Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-24. [PMID: 10697061]
- Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. medRxiv. Preprint posted online 15 July 2020. doi:10.1101/2020.07.15.20151852
- World Health Organization. Q&A : hydroxychloroquine and COVID-19. 19 June 2020. Accessed at on 19 June 2020.
- 20. Kaptein SJF, Jacobs S, Langendries L, et al. Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine. bioRxiv. Preprint posted online 19 June 2020. doi:10.1101/2020.06.19.159053
- Park SJ, Yu KM, Kim YI, et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio. 2020;11. [PMID: 32444382] doi:10.1128/mBio.01114-20
- Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. Research Square. Preprint posted online 6 May 2020. doi:10.21203/-27223/v1
- McMichael TM, Currie DW, Clark S, et al; Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N Engl J Med. 2020;382:2005-2011. [PMID: 32220208] doi:10.1056/NEJMoa2005412
- Ross SB, Wilson MG, Papillon-Ferland L, et al. COVID-SAFER: deprescribing guidance for hydroxychloroquine drug interactions in older adults. J Am Geriatr Soc. 2020. [PMID: 32441771] doi:10.1111/jgs.16623
- World Health Organization. Global surveillance for human infection with coronavirus disease (COVID-19). 20 March 2020. Accessed at ) on 20 March 2020.
Source: PubMed